Added to YB: 2025-12-26
Pitch date: 2025-12-22
VIR [neutral]
Vir Biotechnology, Inc.
+1.83%
current return
Author Info
everyonehatespoetry is an equities analyst sharing his best special situations / GARP ideas, mostly small and micro caps. Sign up for the newsletter.
Company Info
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.
Market Cap
$801.4M
Pitch Price
$6.00
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.80
P/E
-1.59
EV/Sales
23.43
Sector
Biotechnology
Category
value
Orders & awards monitor - week 1 - Vir Biotechnology, Inc.
VIR (update): Licensed tobevibart/elebsiran combo to Norgine for chronic hepatitis delta in EU/ANZ for €55M upfront + €495M milestones. $800M mkt cap, $800M cash ($0 EV) but burning $450M/yr on pipeline development. Significant deal value vs current valuation.
Read full article (1 min)